Taylor Fithian and the Founder-Era Governance Baseline
- Published
- Content last changed
- Public-evidence cutoff
- Sources checked
- Record through
- Editorial status
- Public-source editorial review complete
Core question. What can the founder era tell us about the professional corporation before modern private-equity/MSO integration?
Evidence spine. Historical corporate/County records; founder-era titles; H.I.G. transition; missing share-transfer chronology.
Evidence note. This article relies on public records and distinguishes established fact, party position, allegation, judicial finding, inference and unresolved question. Nothing here is a finding that any identified corporation or individual violated California law unless a cited adjudicative source expressly says so.
Opening frame#
Taylor Fithian and the Founder-Era Governance Baseline is a governance inquiry, not a title-matching exercise. Corporate office, medical leadership, stock ownership, enterprise employment, and practical decision authority are treated as distinct evidentiary categories. The record is strongest where those categories converge in executed documents and weakest where succession or ownership instruments remain unavailable.
The governing question is narrow: What can the founder era tell us about the professional corporation before modern private-equity/MSO integration? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material.
I. The Question and the Public Record#
The relevant public record is best read cumulatively. No single branding statement, county agenda item, corporate filing, bankruptcy disclosure, or management agreement resolves the entire relationship. The evidentiary value comes from comparing documents created for different purposes and asking whether they converge on the same allocation of identity, authority, economics, and professional responsibility.
Rule 7.1 “corporate parent” anomaly#
Several 2023–2024 Northern District dockets show Wellpath LLC identifying CFMG as a “Corporate Parent.” Other filings identify CFMG merely as an “Other Affiliate,” and a 2026 CFMG disclosure reciprocally identifies Wellpath LLC as an “Other Affiliate.” These labels also conflict with the bankruptcy ownership chart and current physician-ownership description.
This is a high-priority reconciliation issue. It is not yet proof that CFMG owned Wellpath LLC, and it should not be dismissed as a typo without the actual disclosure forms.
Why this is analytically important#
If the underlying filings truly say what the docket text says, the record raises an obvious question:
How could a California physician-owned professional corporation be identified in federal corporate-disclosure filings as the “corporate parent” of Wellpath LLC, a national management entity, while public corporate materials describe CFMG as a Wellpath affiliate?
There may be an innocent explanation: ECF relationship categories may have been selected imperfectly, the disclosure might have been drafted for conflicts purposes rather than corporate genealogy, or docket metadata may compress a more nuanced statement.
the record must not turn this into an accusation before reviewing the filings themselves.
But the repetition across more than one case means the issue is sufficiently concrete to justify a dedicated source-retrieval project.
open question: Very High.
Requested source set:
- exact PDF of interested-entity/corporate-disclosure filings in Beckner ;
- exact filings in Sand ;
- exact filings in Strieter ;
- exact filings in Avila ;
- equivalent filings in Venegas , Kukar-Tekano , Ayala , Pugh , and current CFMG cases.
The output should be a year-by-year table showing the relationship box or terminology actually used.
The contract record shows a recurring county-side misdescription#
Multiple county/public sources use formulations such as:
- “CFMG dba Wellpath”
- “CFMG/Wellpath”
- “CFMG, now Wellpath”
- “Wellpath, formerly CFMG”
- “CFMG dba Wellpath Management, Inc.”
- “CFMG commonly known as Wellpath”
These formulations should not be collapsed into one legal proposition.
They may represent:
- brand usage;
- County shorthand;
- vendor-system nomenclature;
- mistaken corporate succession assumptions;
- or actual contractual DBA language.
The federal bankruptcy record proves why this matters: CFMG remained a distinct professional corporation.
Thus county nomenclature is best treated as:
evidence of how the healthcare operation presented itself and was understood by the governmental client.
That is highly relevant to operational identity.
It is not enough to establish corporate genealogy.
Corporate disclosures — affiliate/parent labels as source-tracing material#
Several federal cases include corporate-disclosure entries describing CFMG and Wellpath through “affiliate,” “other affiliate,” or more expansive relationship labels.
These are useful for establishing that a disclosed corporate relationship existed or was represented.
They are poor substitutes for:
- stock ledgers;
- shareholder agreements;
- capitalization tables;
- governance instruments;
- or the MSA.
A Rule 7.1 label should therefore be coded:
relationship representation — authenticate underlying corporate basis.
Exact disclosure language is reproduced here only with:
- case;
- ECF number;
- filing date;
- filing party;
- signatory;
- and surrounding form context.
II. Structural and Historical Context#
From CFMG to the Wellpath Era: A California Corporate Timeline#
The modern CFMG–Wellpath structure is easier to understand when three histories are kept separate: the history of the California professional corporation, the history of the management enterprise around it, and the history of government contracts that continued through those changes.
A common mistake is to tell the story as a straight corporate succession:
CFMG → CMGC → Wellpath
The public documents do not support treating that shorthand as a complete legal genealogy.
A better model is three parallel tracks.
Era 2 — 2012–2018: H.I.G./CMGC and the modern PC–MSO architecture#
An MSA effective December 31, 2012 created the formal division between CFMG professional authority and the management company’s broad administrative functions.
On January 7, 2013, H.I.G. Capital announced a strategic investment in CFMG and described a partnership with founder/president Dr. Taylor Fithian and CFMG management.
Primary source:
https://hig.com/news/h-i-g-capital-announces-strategic-investment-in-california-forensic-medical-group/
By the middle of this period, federal cases begin describing a broader corporate structure around CFMG. In Neuroth v. Mendocino County , the federal record described Correctional Medical Group Companies (“CMGC”) as CFMG’s corporate parent. That description should be treated as a court-record description of the structure, not by itself as a corporate-law adjudication.
Research implication: before the Wellpath name existed, the PC was already embedded in a larger management/holding-company system.
The correct treatment of the overlap#
the record should not invent a precise succession date from Fithian to Herr.
Possible explanations include:
- Fithian retained a founder/former-president title in pleadings describing earlier events;
- Herr assumed formal presidency during the middle of the decade;
- litigation allegations were historically dated rather than contemporaneous;
- different records used policy or medical titles imprecisely.
Until the corporate minutes and Secretary of State history are obtained, the transition should be described as:
By at least April 2015, Raymond Herr was being identified in contemporaneous operational records as CFMG President and Chief Medical Officer; litigation concerning earlier conduct continued to identify founder Taylor Fithian as President.
That formulation preserves the source conflict rather than silently resolving it.
Shareholder-succession event table to build once the agreement is found#
For every historical owner transfer:
The likely historical periods needing reconstruction are:
- founder era;
- 2012–2013 H.I.G. transaction;
- Fithian/Herr transition;
- 2018 CCS–CMGC combination;
- Herr/Bazzel transition;
- 2024 bankruptcy;
- 2025 lender emergence;
- 2026 Local Government–California restructuring.
The chronology should remain blank where ownership is unproven rather than inferring ownership from officer titles.
III. The Control and Governance Analysis#
The central thesis of this investigation#
The public record supports two propositions at the same time:
CFMG remains legally meaningful as a California professional corporation and public contractor.
and
Wellpath supplies a broad operating and management architecture around CFMG.
The next question is not whether those facts can coexist. They plainly can.
The next question is how authority moves through the system.
This series will trace that question across:
- corporate history;
- the management agreement;
- California corporate-practice law;
- county contracts;
- employment and HR systems;
- physician staffing;
- credentialing and privileging;
- medical records;
- utilization and referrals;
- clinical policy;
- finance and banking;
- insurance and claims;
- litigation positions;
- bankruptcy;
- and county-by-county operations.
Where the public record proves something, the investigation will say so.
Where it proves only an allegation, stipulation, company position, or administrative fact, that distinction will remain visible.
And where the public record does not establish who had the final authority, the answer will be open rather than inferred.
Enterprise consolidation#
2015–2017. Raymond Herr, M.D. becomes publicly visible as CFMG President/CMO and authorized official. Litigation and County records later connect him to finance, contracts, staffing, policies, LVN scope, and mortality-review evidence.
October 1, 2018. H.I.G. combines Correct Care Solutions and its CMGC platform, creating the enterprise that becomes Wellpath. This is an enterprise combination; it does not establish that the California professional corporation merged out of existence.
January 1, 2019. The CFMG MSA and related/incidental instruments are assigned to Wellpath LLC. The assignment expressly references relevant stock-transfer restriction agreements. This is the strongest CFMG-specific proof that ownership/succession instruments existed, but not proof of their contents.
Why these documents matter now#
California Attorney General enforcement in 2026 has focused directly on structures in which an MSO or private-equity-backed enterprise can:
- replace a physician shareholder;
- control who succeeds the shareholder;
- make physician ownership dependent on continued use of the MSO;
- prevent the physician practice from replacing the MSO without risking ownership.
That is precisely why the CFMG stock-transfer documents can no longer be treated as incidental corporate paperwork.
The decisive questions are:
- Who could become a CFMG shareholder?
- Who nominated or approved successors?
- Could Wellpath veto a proposed physician shareholder?
- Could Wellpath require replacement of a physician shareholder?
- What happened upon death, disability, loss of licensure, resignation, retirement, termination, or bankruptcy?
- Was any stock held in escrow?
- Did any proxy, option, nominee arrangement, succession list, or power of attorney exist?
- Who fixed the share-purchase price?
- Who funded the purchase?
- Did Wellpath or an affiliate possess a security interest tied to the shares?
- Could a physician owner remain owner after terminating the MSA?
- Could the physician owner sell to another qualified physician without Wellpath approval?
Until these instruments are obtained, no confident conclusion should be made about ultimate ownership succession.
1983–2012 — THE FOUNDING LEADERSHIP MODEL#
CFMG publicly traces its origins to 1983.
Historical public records repeatedly identify Taylor Fithian, M.D. as:
- co-founder;
- President;
- Medical Director.
An older Sonoma County court/grand-jury record includes a letter signed:
Taylor Fithian, M.D. — President and Medical Director, California Forensic Medical Group
Federal litigation arising from 2013 conduct likewise described Fithian as CFMG's co-founder, President, and Medical Director.
In Resendiz , the court's factual background, derived from the complaint, identified Fithian in that capacity.
Other litigation alleged that he had systemwide policy responsibility.
Those litigation descriptions are not necessarily adjudicated corporate facts in every respect, but they consistently establish Fithian as the highly visible physician leader of the pre-H.I.G. CFMG organization.
Two nonphysician executives are also central to the founding-era public narrative:
- Elaine Hustedt — operations/personnel leadership;
- Dan Hustedt — finance leadership.
H.I.G.'s January 2013 announcement described the three-person founding-management partnership as:
- Taylor Fithian — President and Medical Director;
- Elaine Hustedt — Vice President of Operations and Personnel;
- Dan Hustedt — Vice President of Finance.
That public description, however, does not tell the whole governance story.
The same governance record also justifies deeper control review#
Other facts justify investigation rather than a presumption of independence:
- The original MSA was signed by the same CEO on both sides.
- H.I.G. was included in the MSA notice architecture from inception.
- The manager may attend and participate in CFMG governance meetings.
- Company action can be concentrated through a single Company Designee.
- The 2019 assignment transferred stock-transfer restriction agreements into the Wellpath management structure.
- Bazzel came from the pre-merger CCS executive structure.
- Medrano simultaneously holds Wellpath regional medical and CFMG corporate roles.
- CFMG's principal office migrated from California to Wellpath's Tennessee corporate infrastructure.
- Current officers/directors use the same Tennessee administrative locus.
- Current shareholders remain undisclosed in the public evidence.
- The actual stock-succession rules remain missing.
Again, those facts do not establish illegality.
They identify the precise governance records needed to answer the question.
Why the stock-transfer document is different from the MSA#
The Management Services Agreement tells us who administers the business.
The stock-transfer agreement may tell us who ultimately controls the owner of the medical corporation.
That distinction is fundamental.
A lawful MSO can perform extensive administrative services for an independently controlled medical corporation.
Examples may include:
- payroll;
- accounting;
- IT;
- HR administration;
- insurance;
- procurement;
- billing;
- compliance support;
- scheduling support;
- records infrastructure;
- contracting support.
The physician corporation can remain substantively independent if the physician owners retain real authority over professional matters and meaningful governance power over the corporation.
A stock-transfer instrument becomes more consequential because it can affect the person who holds the legal voting stock.
If the MSO merely prevents an unqualified person from inheriting professional-corporation stock and provides an orderly mechanism for transfer to another independently selected qualified physician, the agreement may function as a legitimate compliance and continuity device.
If, by contrast, the MSO can decide who owns the PC, replace the owner at will, or cause the owner to lose stock for challenging the MSO, then the agreement can give the MSO leverage over every decision formally assigned to the physician owner.
The legal inquiry therefore changes from:
“Who performs management services?”
to:
“Who can remove the person who is supposed to control the professional corporation?”
"PATIENT SAFETY" IS WHERE ORDINARY HR AND PHYSICIAN GOVERNANCE MEET#
Where a termination or separation communication invokes clinical safety rather than paperwork alone, the decision stops being an ordinary human-resources matter. A statement that a clinician’s return could endanger the clinician or patients is a clinical judgment in substance, whatever its administrative form — and clinical judgment inside a California professional corporation is reserved to the professional entity, not to the management organization that may administer the paperwork around it.
That is why the decision chain matters more than the wording. The question is not whether an administrator may communicate such a decision; plainly one may. The question is whether the professional judgment underlying it was made by the professional corporation before implementation, or supplied afterwards to explain an act already taken. The proper-channel test and the first-decision test answer different halves of that question: the first asks whether the decision travelled through the body actually holding the authority, the second asks whether professional review preceded or followed the operative act.
Neither half can be answered from a communication alone. A letter establishes that a reason was given at a time. It does not establish who held the decision right, what any professional body reviewed, or whether that review was substantive rather than ratificatory. The records that would answer it — committee minutes, written consents, the contemporaneous decision file, the referral path for a fitness-for-duty question — are not in the public record for this project, and this investigation does not infer their contents from the fact that a decision was communicated.
California's Medical Board guidance states that Business and Professions Code section 2400 is intended to prevent unlicensed persons from interfering with or influencing physician professional judgment.
The Board identifies physician-controlled decisions to include:
- diagnostic testing;
- referrals;
- ultimate patient care;
- and how many patients a physician must see or how many hours a physician must work.
It also identifies management decisions that should remain under licensed-physician control when they control medical practice, including:
- selection, hiring, and firing as it relates to clinical competency or proficiency .
The key qualification is the phrase as it relates to clinical competency or proficiency .
Not every termination of a physician is a medical decision.
A professional corporation can use ordinary HR administrators to investigate attendance, payroll, interpersonal conduct, policy compliance, or other nonclinical matters.
An MSO can provide lawful administrative assistance.
But if the operative reason for continued exclusion or termination is:
this physician cannot safely treat patients,
then the investigation must determine whether a licensed CFMG physician independently made or approved that professional judgment.
That is the strongest CPOM-relevant framing currently supported by the record.
It avoids the overbroad proposition that every physician-HR decision must personally be performed by a physician.
IV. Contrary Evidence, Limits, and Competing Explanations#
A disciplined analysis must begin its limiting case with the strongest contrary evidence: The central limitation is the missing shareholder/stock-transfer record. Physician corporate titles are genuine governance evidence but are not proof of ownership or independence under disagreement.
Current evidence favoring structural independence#
The strongest evidence favoring genuine structural independence includes:
- CFMG remained a separate nondebtor professional corporation during Wellpath bankruptcy.
- Wellpath's own board co-chair publicly stated there was no ownership overlap.
- County materials describe CFMG as a separate physician-owned entity.
- CFMG signs county contracts through physician corporate officers.
- The MSA expressly preserves professional judgment.
- CFMG possesses contractual rights to terminate for material manager breach.
- Management's governance representative is expressly nonvoting.
- CFMG is the covered entity under HIPAA while management is the business associate.
- CFMG appears to own/hold the professional contracts with California counties.
- The MSA contemplates CFMG board evaluation of management performance and bonus determinations.
These facts are meaningful and must remain in the final analysis.
V. Missing Documents and Falsification Tests#
The record remains incomplete in material respects. Key unresolved points include the actual shareholder ledger, stock-transfer agreement, succession minutes, and the explanation for contradictory parent/subsidiary/affiliate filings.
Physician executive succession#
2019–2021. Herr remains central. By September 2021 a Monterey instrument identifies Herr as CFMG President and Judd Bazzel as Treasurer.
By September 2022. Public County agreements show Bazzel as CFMG President and Richard Medrano as Vice President/Secretary. The exact board/shareholder action producing this transition remains missing. No stock transfer should be inferred from officer succession.
By 2025. Corporate records identify Bazzel, Medrano, and Scott Kennedy as CFMG directors/officers. Their shareholder status remains unproved.
The documents that now matter most#
Tier One:
- Every stock-transfer restriction agreement referenced in the 2019 assignment.
- Current CFMG stock ledger.
- Current shareholder agreement.
- Shareholder succession agreements.
- Options, proxies, nominee agreements, powers of attorney.
- CFMG bylaws.
- Company Designee appointments.
- Full Deficit Funding Loan Agreement and amendments.
- UCC-1 financing statements and continuations/terminations.
- Current security agreements.
- Bank signature cards.
- ACH and treasury authorities.
- Deposit-account control agreements.
- 2012 Credit Agreement and successor/refinancing agreements.
- Every MSA amendment since 2012.
- Post-bankruptcy ratification/assumption documents.
- 2025–2026 CFMG board/shareholder minutes.
- Monthly management-company bonus resolutions.
- Management-fee/FMV analyses.
- Current New WPCC Parent capitalization and governance agreements.
Tier Two:
- Intercompany ledgers.
- CFMG general ledger.
- Wellpath management-fee invoices.
- Deficit-funding advance history.
- Insurance/claims agreements.
- IT/data exit provisions.
- county change-of-MSO approval provisions.
- employment/personnel transition restrictions.
- Local Government–California delegation matrix.
- documents showing whether CFMG considered alternative managers during bankruptcy.
CFMG Shareholders, Directors, Officers, Company Designees, Stock Succession, Cross-Roles, and the Search for the Missing Stock-Transfer Agreements#
the prior analysis establishes why ownership succession is the top unresolved structural issue.
the prior analysis should reconstruct:
- every identifiable CFMG shareholder;
- every president/CEO/secretary/CFO;
- every Company Designee;
- overlap with CMGC/Wellpath roles;
- corporate signature history;
- death/resignation/retirement succession events;
- public filings and county contracts;
- historical H.I.G./CMGC transaction representations;
- the most likely repositories for the missing stock agreements.
Only after that chain is reconstructed should the investigation draw any conclusion about who ultimately controlled CFMG ownership.
After six volumes, the most important remaining structural question is ownership.
This article produces a significant clarification:
The public record now permits a reasonably strong reconstruction of CFMG's corporate officers and directors over time, but it still does not identify the current CFMG shareholders or their percentages with sufficient reliability.
That distinction is critical.
A person can be:
- a physician;
- an officer;
- a director;
- a president;
- a chief executive officer;
- a Company Designee under the MSA;
- a medical director;
- a Wellpath executive;
- and even the person signing CFMG contracts
without necessarily being a shareholder.
Conversely, a shareholder may hold no public operating title.
Accordingly, officer succession cannot be treated as proof of stock succession .
The strongest current governance evidence is:
- the 2012 MSA;
- county contracts signed under California corporate formalities;
- California Secretary of State Statements of Information;
- federal litigation;
- labor agreements;
- the Wellpath bankruptcy;
- Wellpath public corporate materials.
Those records establish who held many formal offices.
They do not disclose the stock ledger.
The stock-transfer restriction agreements expressly referenced in the 2019 assignment therefore remain the single most important missing ownership source.
Shareholder#
The shareholder owns the professional corporation's stock.
Because CFMG is a California professional medical corporation, stock ownership is subject to California professional-corporation restrictions.
A shareholder's identity must be established through:
- stock ledger;
- stock certificate;
- shareholder agreement;
- transfer record;
- corporate minutes;
- authenticated corporate filing or admission.
A title alone is insufficient.
The current shareholder question remains unanswered#
This is perhaps the most important conclusion of the prior analysis.
The January and November 2025 California Statements of Information tell us:
- officers;
- directors;
- addresses.
They do not tell us:
- shareholders;
- share percentages;
- stock certificates;
- beneficial ownership;
- succession rights.
Wellpath has publicly described CFMG as physician-owned.
Kip Hallman publicly described it as owned primarily by a group of physicians and said there was no ownership overlap with Wellpath.
Those are meaningful corporate statements.
But the actual ownership schedule has not yet been obtained.
Accordingly, the record should not publish:
- "Bazzel owns CFMG";
- "Bazzel, Medrano and Kennedy are the shareholders";
- "Taranath is a CFMG shareholder";
- "Wellpath owns CFMG";
- "H.I.G. owns CFMG stock."
None of those propositions is currently established by sufficiently reliable primary evidence.
The stock-transfer restrictions could explain the succession pattern — but the documents are missing#
The 2019 assignment's express reference to "relevant stock transfer restriction agreements" becomes more important when placed beside the officer succession.
At least three major physician-leadership transitions occurred:
- Fithian era → Herr era;
- Herr era → transitional O'Bryan/Bazzel period;
- Bazzel era → current three-director board.
The unresolved question is whether any of these officer transitions coincided with stock succession.
Questions:
- Did Fithian sell or transfer shares?
- Did Herr acquire shares?
- Did Bazzel acquire shares?
- Were Medrano or Kennedy issued shares?
- Was a single physician shareholder replaced while board offices changed around that person?
- Did Wellpath or its predecessor have contractual approval over the transferee?
- Was stock held subject to a transfer restriction favoring the MSO?
- Did a physician's employment status affect ownership?
Those questions cannot be answered from public officer titles.
The stock documents are necessary.
THE WELLPath CFMG / CFMG HOLDINGS ENTITY MAY HELP EXPLAIN HISTORICAL CONFUSION ABOUT "PARENT" STATUS#
The discovery that Wellpath CFMG, Inc. was formerly CFMG Holdings Corp. provides a new interpretive clue.
Federal and other records have at times used descriptions such as:
- CFMG parent;
- CFMG subsidiary;
- CFMG affiliate;
- CMGC parent.
Some of those descriptions may reflect genuine relationships.
Some may reflect shorthand.
And some may be complicated by the coexistence of:
- the professional corporation;
- CFMG Holdings Corp.;
- Correctional Medical Group Companies;
- Wellpath CFMG, Inc.;
- Wellpath Management.
This is especially important for the unresolved Rule 7.1 corporate-disclosure anomaly identified in the prior analysis.
The correct next step is not to infer that the disclosures are wrong.
It is to retrieve the exact filed forms and identify which legal CFMG entity the disclosure actually names .
The naming collision is a plausible source of confusion, but that remains an inference until the filings are reviewed.
Primary documents now required to complete the ownership chain#
The next document-production/retrieval priority is:
- CFMG stock ledger from 2012 to present.
- Every issued/cancelled stock certificate.
- Shareholder roster by year.
- Share percentages.
- CFMG shareholder agreements.
- Stock-transfer restriction agreements referenced in 2019 assignment.
- Buy-sell agreements.
- succession agreements.
- options.
- proxies.
- nominee/custodial agreements.
- death/disability succession provisions.
- license-loss succession provisions.
- employment-linked stock provisions.
- retirement/resignation transfers.
- board approvals of every stock transfer.
- shareholder approvals.
- valuations/purchase-price records.
- source of funds for each transfer.
- any MSO consent/veto rights.
- any security interest involving shares.
- all Company Designee appointments.
- bylaws from 2012 to present.
- articles/amendments.
- Statements of Information for every year available.
- board/director minutes.
- shareholder meeting minutes.
- written consents.
- conflict-of-interest policies.
- 2012 MSA approval resolutions.
- 2019 assignment approval resolutions.
- post-bankruptcy MSA ratification/continuation resolutions.
- 2026 Local Government–California authorization records.
Why bankruptcy is a true governance stress test#
The ordinary PC–MSO relationship asks whether a physician-owned professional corporation is genuinely independent while buying administrative support from a management company.
Chapter 11 adds a much harder question:
What does the physician corporation do when its exclusive manager becomes insolvent, enters Chapter 11, changes owners, and reorganizes the operating structure?
For an independent principal, that event should at least create the possibility of:
- evaluating the manager’s solvency;
- assessing contract breach/default rights;
- evaluating alternative managers;
- deciding whether to continue the MSA;
- reassessing management fees;
- obtaining independent legal advice;
- examining data/records continuity;
- considering malpractice and insurance continuity;
- evaluating effects on physician employment;
- approving any required assignment or post-emergence transition;
- and documenting the physician board’s judgment.
A decision to remain with Wellpath could be entirely rational.
The test is not whether CFMG changed managers.
The test is whether CFMG exercised an identifiable independent corporate choice .
To date, this investigation has not identified publicly filed CFMG board minutes, shareholder resolutions, independent-counsel memoranda, or other CFMG-specific governance records documenting such a decision.
That absence must be interpreted cautiously.
CFMG was a nondebtor professional corporation. Its internal board materials were not necessarily required to be filed in the Wellpath bankruptcy.
Thus the correct conclusion is not:
“CFMG’s board did nothing.”
The correct conclusion is:
The public bankruptcy record reviewed to date contains extensive evidence of what Wellpath’s Debtors sought to preserve in the PC relationships, but comparatively little public evidence of what CFMG’s physician board independently decided about continuing that relationship.
That asymmetry itself defines the next documentary inquiry.
The bankruptcy motion directly confirms stock-transfer agreements#
Before the bankruptcy review, the strongest evidence of CFMG stock-transfer restrictions came from the January 2019 assignment, which expressly transferred related instruments including “relevant stock transfer restriction agreements.”
Docket No. 15 materially strengthens that evidence at the enterprise level.
The Debtors disclosed that, in addition to PC Management Services Agreements, they and certain physician owners were parties to:
Stock Transfer Agreements
that:
- restrict transfer of a physician owner’s stock;
- facilitate a streamlined transition of ownership;
- promote compliance with state professional-entity requirements;
- address transfer events such as death and disability;
- promote continuity of care;
- and promote the continuation of administrative services by the Debtors .
The Debtors further stated:
Under the Stock Transfer Agreements, the Debtors have authority to ensure that the Professional Corporation is duly licensed and qualified.
This is one of the most important new findings in the entire record.
It establishes that stock-transfer arrangements were not merely passive restrictions designed to prevent transfer to an unlicensed person.
At least at the enterprise level, the Debtors themselves described the agreements as tools tied to:
- ownership transition;
- licensing continuity;
- and continuation of the Debtors’ management relationship.
That is precisely the type of contractual architecture California’s 2026 Art Center and Carbon Health enforcement developments make significant.
But a crucial limitation remains.
Docket No. 15 speaks generically about “certain PC Physicians.”
It does not publish the CFMG-specific Stock Transfer Agreement or state that every provision described applies identically to CFMG.
The CFMG connection is nevertheless stronger than a generic inference because the 2019 CFMG assignment independently confirms that relevant stock-transfer restriction agreements existed in the CFMG relationship .
The two sources therefore fit together:
2019 CFMG Assignment: CFMG-related stock-transfer restrictions existed and were assigned into the Wellpath structure.
2024 PC Motion: Wellpath explains the purposes and functions of Stock Transfer Agreements in its friendly-PC model generally.
The remaining question is the exact CFMG text.
The missing CFMG board record should not be treated as evidence of absence#
Because CFMG was a nondebtor, its ordinary board minutes would normally remain private corporate records.
A bankruptcy court generally does not require every nondebtor counterparty to publish internal deliberations merely because its contract partner files Chapter 11.
Therefore:
No public CFMG board minutes found ≠ no CFMG board deliberation occurred.
But where the substantive question is physician independence, those records become the best direct evidence.
The public record should therefore say:
No publicly filed CFMG board record has yet been identified showing how its physicians evaluated the manager’s bankruptcy and ownership transition.
That is accurate and neutral.
Article v.f makes the missing stock agreements more, not less, important#
One might initially assume that confirmation rendered the stock-transfer issue irrelevant. The opposite is true.
If the MSA was broadly assumed together with related agreements and interests, then determining the exact scope of the CFMG-related instruments becomes even more important.
The 2019 Assignment expressly links the MSA, related/incidental instruments, and stock-transfer restriction agreements. The bankruptcy PC Motion separately describes stock-transfer agreements as part of the friendly-PC system and says they support continuity of Debtor administrative services. Article V.F then uses broad language about modifications, amendments, supplements, restatements, related agreements, options, rights, and interests.
The convergence of those documents means the CFMG-specific stock instrument should now be treated as a Plan-continuity document , not merely a historical ownership document.
The exact instrument could reveal whether ownership-succession control also crossed the May 9, 2025 restructuring boundary.
The “real disagreement” test remains the gold standard#
Even after the stock agreement is obtained, actual conduct will remain important.
The best evidence of real independence would be a documented disagreement in which:
- Wellpath wanted one result;
- the CFMG physician owner/board wanted another;
- the physician decision prevailed;
- and the physician did not lose employment, ownership, or corporate authority.
Examples could include:
- rejecting a termination recommendation;
- rejecting a patient-volume target;
- modifying compensation;
- approving a referral despite cost concerns;
- refusing an enterprise clinical policy;
- replacing an MSO executive liaison;
- withholding a management bonus.
The best evidence of capture would be the opposite:
- physician resists;
- Wellpath threatens/uses stock or employment rights;
- physician is replaced;
- decision changes.
This is why contract rights and real-world events must ultimately be paired.
A reported physician decision does not, by itself, complete the decision chain#
A governance question can be posed publicly without any private record: if a future public filing, deposition or produced document shows physician participation in a specific personnel decision, that would be direct evidence of professional governance in operation. Until then the question stays open.
The same sequence applies to any public decision event through the same sequence used elsewhere in the series: origin → recommendation → authorized professional review → approval or veto → implementation . A later physician ratification is not the same as an originating decision; a management recommendation is not the same as final authority; and mere alignment does not reveal who would prevail under disagreement.
The highest-value evidence is a conflict-tested record showing that an authorized CFMG physician body could say no and that the enterprise was required to follow its decision—or the reverse. Until such a public record is available, private personnel material should remain a research lead rather than a published merits proposition.
Tier-one open evidence#
The highest-value missing items remain:
- CFMG-specific stock-transfer restriction / succession agreement.
- CFMG stock ledger and shareholder roster by year.
- CFMG bylaws and Company-Designee appointments.
- Proxy, option, stock-power, escrow, nominee, or power-of-attorney instruments.
- Docket 194 CFMG assumption/cure row and proposed cure amount.
- CFMG board/shareholder minutes from the bankruptcy and emergence period.
- Deficit Funding Loan Agreement.
- UCC/security-interest records.
- Cash/bank signature and treasury authorities.
- Monthly CFMG management-bonus resolutions.
- Smith ECF 156 and full financial-discovery record.
- Full Overfield Chapman termination file/approval chain.
- Utilization-management denial/appeal/override records.
- Current Local Government–California delegation matrix.
- Post-emergence MSA/stock-instrument amendments or reaffirmations.
VI. Why the Issue Matters#
The stakes are practical rather than semantic. Counties need to know which entity is accountable for contracted performance; clinicians need to know where professional authority resides; courts and regulators need entity-specific evidence rather than brand shorthand; and the public needs a record that distinguishes corporate continuity from operational integration. Those distinctions become most important when the actors disagree, when a contract changes hands, when a professional decision conflicts with an economic preference, or when litigation requires a precise answer to who had authority to act.
VII. Falsification Tests and Evidentiary Limits Note#
The record does not support be read as establishing an unproven motive, an undisclosed shareholder, an unlawful medical override, or a legal conclusion that a court or regulator has not made. The strongest version of the thesis is the one that survives the missing-document test: identify the instrument, minutes, ledger, delegation, approval record, or disagreement event that would materially change the conclusion, then state what has and has not been found. If later primary evidence contradicts a proposition stated here, the correction should be made at the proposition level rather than defended through branding or organizational shorthand.
VIII. Related Articles#
- Article 020 — Who Could Say No? The Demonstrated-Veto Test for Professional Independence
- Article 022 — Raymond Herr: The Physician Executive Who Bridges CFMG and the Enterprise
- Article 019 — Could CFMG Actually Leave Wellpath? The Right-to-Leave Test
The proposition to be tested#
The central proposition in this article is not that every appearance of the Wellpath name proves control, nor that formal CFMG separateness ends the inquiry. The proposition to be tested is narrower: What can the founder era tell us about the professional corporation before modern private-equity/MSO integration? A serious legal brief should state that proposition before discussing motive, liability, or remedy because the same document can be highly probative on one dimension and nearly irrelevant on another.
For this subject, the principal evidentiary dimensions are founder-era baseline, ownership history, pre-MSO governance, and succession. The source spine identified in the current public record is: Historical corporate/County records; founder-era titles; H.I.G. transition; missing share-transfer chronology. Those sources should not be pooled as though they were interchangeable. A county contract speaks most reliably to the county's counterparty and purchased obligations. A management agreement speaks to contractual allocation between the professional corporation and manager. A court order speaks to the matter actually adjudicated. A party filing or corporate announcement remains a representation unless independently adopted or found by a tribunal.
Governance evidence must distinguish office, employment, management title, board membership, shareholder status, delegated authority, and signature authority. These categories can overlap in one person without becoming legally interchangeable. The relevant capacity must be identified for each act. The practical advantage of that method is that it prevents a common failure in complex-enterprise investigations: using a true fact about one relationship as proof of a different relationship. A shared brand may show integration; a W-2 may show payroll identity; a contract signature may show authority to bind a corporation; an officer title may show corporate office. None automatically proves stock ownership or final clinical authority.
The charging or enforcement threshold, if any regulator ever considered one, would therefore require an evidence chain rather than a collage: identify the protected or regulated function; identify the actor with formal authority; reconstruct the first operative decision; identify the person or entity that could approve, reject, modify, or reverse it; and verify who implemented the result. Until that chain is complete, the proper classification is evidence, inference, or unresolved question—not adjudicated fact.
Weighing the evidence#
The evidentiary hierarchy for Taylor Fithian and the Founder-Era Governance Baseline should begin with contemporaneous primary instruments and end with retrospective shorthand. Executed contracts, amendments, assignments, board resolutions, authenticated corporate records, court orders, government payroll or labor records, and formal agency records ordinarily deserve more weight on the proposition they were created to establish than marketing language or later summaries. Even among primary materials, however, purpose matters. A contract can establish contractual rights without proving that those rights were exercised; a tax record can establish reporting without deciding every common-law employer factor; a bankruptcy schedule can establish debtor treatment without answering professional-governance questions for a nondebtor corporation.
The article's existing record illustrates why that hierarchy matters.ithin its evidentiary lane. Several 2023–2024 Northern District dockets show Wellpath LLC identifying CFMG as a “Corporate Parent.” Other filings identify CFMG merely as an “Other Affiliate,” and a 2026 CFMG disclosure reciprocally identifies Wellpath LLC as an “Other Affiliate.” These labels also conflict with the bankruptcy ownership chart and current physician-ownership description.
A prosecutor, defense lawyer, regulator, or investigative editor should ask five questions of every source: Who created it? What legal or business purpose did it serve? What date and entity does it concern? Is the statement a recital, operative term, allegation, stipulation, finding, or marketing representation? What independent record could confirm or contradict it? Applying those questions consistently is more valuable than multiplying citations that all derive from the same underlying assertion.
This also defines how contradictions should be handled. When two records use different labels, the first step is not to accuse one of being false. The first step is to determine whether the records were answering different questions. Only after normalizing entity, date, capacity, forum, and purpose should a remaining contradiction be treated as substantive. That discipline makes the article stronger for both sides because it identifies where the record genuinely conflicts and where the conflict is merely semantic.
How each source is used#
The following public authorities are tied to defined propositions in this article. They are not interchangeable: each is cited for the institutional purpose it can actually prove, and none is treated as a universal finding about ownership, employment, liability, or professional control.
- H.I.G. Capital, 'H.I.G. Capital Announces Strategic Investment in California Forensic Medical Group,' Jan. 7, 2013. Used here as first-party transaction evidence for the 2013 investment and founder-era enterprise history, but not a shareholder ledger for the California professional corporation.
- 2012 CFMG Management Services Agreement — California Forensic Medical Group, Incorporated and California Forensic Management Group, Inc., Dec. 31, 2012. Used here as operative baseline for the allocation of management functions, physician-reserved responsibilities, and the manager/professional-corporation relationship.
- 2019 Assignment of Management Services Agreement, effective Jan. 1, 2019 — CFMG remained the Company while Wellpath LLC became the Manager. Used here as dated evidence of management succession without, by itself, eliminating CFMG's separate professional-corporation identity.
- H.I.G. Capital, 'Correct Care Solutions and Correctional Medical Group Companies Join Forces,' Oct. 1, 2018. Used here as first-party transaction evidence for the 2018 enterprise combination and subsequent Wellpath-era branding.
- Wellpath, 'Wellpath Announces Creation of a New Operating Division in California,' Mar. 13, 2026. Used here as Wellpath's current public description of its California operating layer and its relationship with CFMG.
- Johnson v. County of Alameda, N.D. Cal. No. 3:23-cv-04069, ECF No. 76 (Mar. 2026). Used here as a public litigation correction distinguishing CFMG from Wellpath Management, Inc. and the debtor-side entities.
Sources and authorities#
- H.I.G. Capital, 'H.I.G. Capital Announces Strategic Investment in California Forensic Medical Group,' Jan. 7, 2013 — https://hig.com/news/h-i-g-capital-announces-strategic-investment-in-california-forensic-medical-group/
- 2012 CFMG Management Services Agreement — California Forensic Medical Group, Incorporated and California Forensic Management Group, Inc., Dec. 31, 2012 — https://www.prisonlegalnews.org/news/publications/california-forensic-medical-group-incorporated-management-services-agreement/
- 2019 Assignment of Management Services Agreement, effective Jan. 1, 2019 — CFMG remained the Company while Wellpath LLC became the Manager — https://www.prisonlegalnews.org/media/publications/California\_Forensic\_Medical\_Group\_Assignment\_of\_Management\_Services\_Agreement.pdf
- H.I.G. Capital, 'Correct Care Solutions and Correctional Medical Group Companies Join Forces,' Oct. 1, 2018 — https://hig.com/news/correct-care-solutions-and-correctional-medical-group-companies-join-forces-to-deliver-best-in-class-healthcare/
- Wellpath, 'Wellpath Announces Creation of a New Operating Division in California,' Mar. 13, 2026 — https://wellpathcare.com/2026/03/13/wellpath-announces-creation-of-a-new-operating-division-in-california-appoints-new-highly-experienced-leader/
- Johnson v. County of Alameda, N.D. Cal. No. 3:23-cv-04069, ECF No. 76 (Mar. 2026) — https://docs.justia.com/cases/federal/district-courts/california/candce/3%3A2023cv04069/416712/76
Citation rule: These sources support only the propositions identified in the article and source analysis. A party filing remains a party position unless adopted by a court; a corporate announcement remains a corporate representation; a contract proves allocated rights but not necessarily implementation; and a regulator's guidance or enforcement position is not an adjudication against CFMG unless a cited matter says so.